On the first episode of Presbyopia Playbook Mark Schaeffer, OD, FAAO clinical excellence captain at MyEyeDr in Birmingham, AL, and founding member and Vice President of the Intrepid Eye Society and Jacob Lang, OD, FAAO, Medical Director of the Dry Eye Service and Ocular Disease Residency Programs at Associated Eye Care in Hudson, WI, and Stillwater, MN, discuss pilocarpine concentration, tolerability, and patient selection.
There has been a clinical shift toward presbyopia drops as a more common pharmacological means to correct near vision in patients aged 40 to 50. While several FDA-approved drops operate on similar mechanisms, they differ in formulation and concentration, raising questions about their efficacy and safety profiles.
Pilocarpine concentration and mechanism of action
These drops primarily function by inducing miosis, effectively enhancing depth of focus through a pinhole effect.1 A critical inquiry emerges: What is the optimal concentration that sufficiently enhances near vision while minimizing side effects?
Insights from related medications such as atropine, phenylephrine, and cyclopentolate suggest that varying concentrations can yield different clinical outcomes.
Tolerability and side effects
Dr. Lang emphasizes that excessive amounts of anything can harm patients, and with miotics, this can lead to increased side effects.
High concentrations of pilocarpine can lead to adverse events such as:2
- Dimming of vision
- Headaches or "brow ache"
- Myopic shifts
- Redness, stinging, or burning upon installation
- Excessive ciliary muscle contraction
Furthermore, excessive miosis may induce negative optical effects, such as diffraction or restricted light entry,3 which can detract from the patient's visual experience.
Download the cheat sheet here!
Approved and Emerging Presbyopia Drops Cheat Sheet
Use this cheat sheet to compare pilocarpine concentrations, adverse events, and key clinical information at a glance.
Patient selection and compliance for presbyopia drops
Dr. Schaeffer likens the role of lower concentration drops for patients under 50 with some accommodative ability to that of a gym spotter—providing just enough assistance to accomplish a visual task effectively.
When selecting candidates for pilocarpine treatment, several factors must be assessed, including lifestyle, motivation, and any history of refractive surgery. Tailoring the choice of drops to fit a patient's unique lifestyle and sensitivity to side effects is crucial. Since these drops are viewed as optional "lifestyle" medications, patients are generally less tolerant of adverse effects compared to those associated with sight-saving treatments like glaucoma medications.
Interestingly, patients who have undergone refractive surgery, such as LASIK, often demonstrate heightened motivation to use these drops. However, caution is advised if their pre-surgery refractive error or axial length is unknown.
Best practices for prescribing presbyopia drops
Dr. Lang emphasizes that presbyopia drops should be considered a viable alternative alongside traditional solutions like glasses and contact lenses. Practitioners should seize the opportunity to offer pharmaceutical refractive correction.
Managing patient expectations through thorough education during consultations is vital for fostering long-term adherence to treatment. Informing patients that side effects may occur, but often improve within the initial weeks, can enhance compliance and satisfaction.
Conclusion
As the landscape of vision correction evolves, pilocarpine drops present an exciting option for addressing presbyopia. By understanding the relationships among concentration, tolerability, and patient selection, eyecare providers can optimize treatment outcomes and improve their patients' quality of life.
